Why women were left out of clinical trials, and what changed

The exclusion of women from clinical research was not an oversight. It was policy, it was written down, and it was defended with reasons. Understanding those reasons matters, because one of them is still operating.

Key points

• Women were formally excluded from many early drug trials.
• Later inclusion rules improved representation but not always analysis.
• Recruitment numbers alone do not guarantee useful evidence.

1977: the guidance

In 1977 the US Food and Drug Administration issued guidance recommending that women of childbearing potential be excluded from phase one and early phase two drug trials. The policy followed concern about fetal exposure to investigational medicines. [1]

The recommendation was applied broadly to premenopausal women capable of becoming pregnant, creating exclusions that extended beyond an individual assessment of pregnancy risk. [1]

The second reason

Alongside the protective argument sat a quieter methodological one. Hormonal cycling introduced variance. A sample of men produced cleaner data.

This reasoning has a hidden premise: that the male body is the general case and the female body is the general case plus complications. Once that premise is accepted, excluding women looks like good study design rather than a decision to learn less about half the population.

That premise is the part that outlived the guidance.

1993: the Revitalization Act

The NIH Revitalization Act of 1993 required the inclusion of women and minority groups in NIH-funded clinical research and addressed analysis of differences. In the same year, FDA guidance moved away from the 1977 exclusionary approach. [2] [3]

This was a real change and enrolment shifted substantially afterwards. But it fixed the input, not the accumulated stock. Every drug approved before 1993 had been evaluated under the old regime, and many of them are still prescribed.

What inclusion did not fix

Analysis. Enrolling women and analysing them separately are different commitments. Pooled results can hide a real difference in effect or adverse event rate by sex. Reporting practice has improved but remains inconsistent across journals and fields.

Dosing. Where sex differences in pharmacokinetics exist, they were often identified retrospectively, after a drug was in wide use.

Which conditions get studied at all. Inclusion rules govern who takes part in the trials that happen. They do not create trials for conditions that were never prioritised. Endometriosis, adenomyosis, menopause symptoms, pelvic pain and postpartum complications remain under-researched relative to how many people they affect.

Life stage. Pregnant and breastfeeding women are still routinely excluded, which leaves clinicians prescribing in pregnancy on thin evidence. The protective instinct that produced the 1977 guidance has migrated rather than disappeared.

Where that leaves the field

The formal barriers are largely gone. What remains is a stock of evidence built without women, a set of habits about what counts as clean data, and a funding pattern that has not caught up with disease burden.

Read the wider picture in the women's health data gap, or the specific methodological version of this problem in the menstrual cycle is still treated as noise in clinical research.

References

1. US Government Accountability Office. Women’s Health: Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement. 2001.
2. US Congress. NIH Revitalization Act of 1993. Public Law 103-43.
3. US Food and Drug Administration. Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs. 1993.